ASCO GU 2019: Randomized Phase III Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning

San Francisco, CA (UroToday.com)  Salvage radiotherapy (SRT) for prostate cancer biochemical recurrence after radical prostatectomy (RP) is commonly administered to patients with PSA < 1 ng/mL, a threshold at which standard-of-care imaging is not sensitive enough to detect disease recurrence.  68Ga-PSMA-11 PET/CT (PSMA) PET/CT molecular imaging is highly sensitive for detecting regional and distant metastatic recurrent prostate cancer at low PSA levels. This lead to the assumption that PSMA can help guide and improve SRT.  

A recent multicenter retrospective study in 270 patients with early biochemical recurrence (PSA<1.0 ng/ml), following RP was conducted. The results demonstrated that PSMA PET/CT had a major impact in 19% of patients undergoing SRT by showing lesions outside the standard radiation field. Most frequent localization of out of field lesions was in the bone and the perirectal area. According to Dr. Calais,  this retrospective study justified conducting a randomized phase 3 imaging trial of SRT with or without PSMA PET/CT investigating its potential benefit on clinical outcome.

In this presented randomized phase 3 trial ,presented in a poster format, the defined goal was to evaluate the success rate of SRT for biochemical recurrence following RP with and without planning based on PSMA scan. In this poster, Dr. Calais presented the protocol of this randomized trial. According to the protocol, a total of 193 patients will be randomized to either a control arm (standard SRT, n=90) and an intervention arm (PSMA PET/CT prior SRT planning, n=103). The primary endpoint is the success rate of SRT measured as biochemical progression-free survival. The secondary endpoints include 5-year biochemical progression-free survival from initiation of SRT, metastasis-free survival, initiation of additional salvage therapy after completion of SRT, and change in initial treatment intent. Patients will be followed for five years, and the trial design is shown in figure 1.

Figure 1 – Trial design:
Randomized Phase III Trial of 68GaPSMA11 PETCT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning

The choice of treating the prostate bed with or without treating the pelvic lymph nodes, and with or without androgen deprivation therapy, is left to the discretion of the treating radiation oncologist. According to the trial protocol, the treating radiation oncologist may or may not change the radiotherapy plan depending on the PSMA findings. Any other imaging is allowed for SRT planning if done per routine care.  

Lastly, the main issues and pitfalls of the study include: 
  1. Drop-out of patients randomized to the control arm
  2. Potential FDA approval of PSMA PET imaging probes in the near future (no randomization to standard arm would be then acceptable).  
This is the first prospective randomized phase 3 trial designed to determine whether PET/CT can improve the outcome of SRT in patients with biochemical recurrence, and we eagerly await its results. 

Presented by: Jeremie Calais, MD, MSc, Assistant Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology, UCLA Nuclear Medicine Department, Los Angeles, CA

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre @GoldbergHanan at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium, (ASCO GU) #GU19, February 14-16, 2019 - San Francisco, CA

Related Content
Randomized Prospective Phase III Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT] - Beyond the Abstract
Everyday Urology - Oncology Insights
Publications focusing on urologic cancer treatments through original manuscripts
By Phillip J. Koo, MD
Experts at Harvard Business School first coined the term disruptive innovation to describe how small, poorly resourced companies could successfully challenge larger ones.1 More than two decades later, this concept is central in medicine, where innovations in everything from proteomics and wearables to electronic health records and health economics are upending our status quo.2,41
By Karen E. Linder, MS, PHD
Prostate cancer [PCa] affects 1 man in 7 in the United States, making this the most commonly diagnosed non-cutaneous cancer in males.  Although an ever-increasing number of treatment options exist, an estimated 26,100 men will still die of the disease in the US in 2016, generally after primary local and systemic treatments for prostate cancer have failed.
Conference Coverage
Recent data from conferences worldwide
Presented by Stefano Fanti, MD
Barcelona, Spain (UroToday.com) Theranostics is an emerging field of medicine which utilizes targeted cancer therapy based on specific molecular-targeted diagnostic tests. As part of the Imaging in Prostate Cancer plenary session at the 2019 European Association of Urology (EAU) annual meeting in Barcelona, Spain
Presented by Olivier Rouvière, MD, PhD
Barcelona, Spain (UroToday.com) Dr. Rouviere presented the imaging specialist’s perspective on MRI use in prostate cancer. According to the European Association of Urology (EAU) guidelines prostate multiparametric MRI (mpMRI) was originally recommended after a negative prostate biopsy
Presented by Michael Hofman, FRACP, MBBS
San Francisco, CA (UroToday.com) PSMA is over-expressed in all prostate tissue, including prostatic carcinoma. Lutetium-177 (177Lu)-PSMA617 (LuPSMA) is a small radiolabeled molecule which binds to PSMA
Presented by Jeremie Calais, MD, MSc
San Francisco, CA (UroToday.com)  Salvage radiotherapy (SRT) for prostate cancer biochemical recurrence after radical prostatectomy (RP) is commonly administered to patients with PSA < 1 ng/mL, a threshold at which standard-of-care imaging 
Presented by Paul L. Nguyen, MD
Prague, Czech Republic (UroToday.com) Dr. Paul Nguyen took the stance for radiation therapy in this much-anticipated debate regarding appropriate local treatment in men with high risk localized prostate cancer. Dr. Nguyen notes that high-quality radiation therapy for high-risk disease needs long-term ADT and a brachytherapy boost.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe